Golvatinib (E7050) restores chemosensitivity in multidrug-resistant cancer cells by inhibiting ABCG2 transporter
Pathology - Research and Practice · 2026
DOI: 10.1016/j.prp.2026.156663 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology - Research and Practice, 2026. Verfasst von Xuan-Yu Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Science, College of Pharmacy and Health Science, St John's University, Queens, NY 11439, USA. Hauptthemen laut MEDLINE: ATP Binding Cassette Transporter, Subfamily G, Member 2, Drug Resistance, Neoplasm, Drug Resistance, Multiple, Neoplasm Proteins. Die Arbeit nennt 49 Literaturangaben.
Abstract (Originalsprache)
ABCG2-mediated drug efflux is a major cause of multidrug resistance (MDR), reducing the activity of various anticancer agents. This study evaluated the role of Golvatinib, originally developed as a c-MET/VEGFR2 inhibitor, as a potential ABCG2 modulator in ABCG2-expressing MDR cells. Golvatinib significantly restored cellular sensitivity to representative ABCG2 substrates, by inhibiting efflux of substrates and increasing intracellular drug accumulation. ABCG2 expression and membrane localization remained unchanged, indicating that this reversal was not due to downregulation or relocation of ABCG2 transporter. Cellular thermal shift analysis supported direct engagement of Golvatinib with the ABCG2 transporter, and apoptosis assay showed that the combination restored chemotherapy-induced cell death in MDR cancer cells. In addition, chemosensitization remained significant in 3D spheroid cell culture. Molecular docking with ABCG2 predicted that Golvatinib binds within the transmembrane drug-binding pocket, consistent with competitive/steric inhibition of substrate transport. These results support the rationale of Golvatinib as a candidate for combination therapy strategies targeting ABCG2-related MDR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Science, College of Pharmacy and Health Science, St John's University, Queens, NY 11439, USA.
- University of Lübeck, Lübeck Institute of Experimental Dermatology, Medicinal Chemistry and Systems Polypharmacology, University Hospital Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany;…
- Department of Pharmaceutical Science, College of Pharmacy and Health Science, St John's University, Queens, NY 11439, USA. Electronic address: chenz@stjohns.edu.
Zitieren
APA
Chen, X. Y., Cao, L. Q., Chen, X., Patel, H., Daartey, A. B., Lan, Y., He, X., Wu, Z. X., Agarwal, S., Stefan, S. M., & Chen, Z. S. (2026). Golvatinib (E7050) restores chemosensitivity in multidrug-resistant cancer cells by inhibiting ABCG2 transporter. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2026.156663
Vancouver
Chen XY, Cao LQ, Chen X, Patel H, Daartey AB, Lan Y, et al. Golvatinib (E7050) restores chemosensitivity in multidrug-resistant cancer cells by inhibiting ABCG2 transporter. Pathology - Research and Practice. 2026. doi:10.1016/j.prp.2026.156663
BibTeX
@article{Chen2026,
author = {Chen, Xuan-Yu and Cao, Lu-Qi and Chen, Xiang and Patel, Harsh and Daartey, Abel B and Lan, Yanning and He, Xinman and Wu, Zhuo-Xun and Agarwal, Saurabh and Stefan, Sven Marcel and Chen, Zhe-Sheng},
title = {Golvatinib (E7050) restores chemosensitivity in multidrug-resistant cancer cells by inhibiting ABCG2 transporter},
journal = {Pathology - Research and Practice},
year = {2026},
doi = {10.1016/j.prp.2026.156663}
}
EUVIMED